Overview

• Memo No. Pb/2025/3896-3104 orders an immediate stop to use, issue and procurement of the listed batches across government facilities.
• The suspension covers specific lots of normal saline, dextrose 5%, ciprofloxacin 200 mg, DNS 0.9%, N/2 plus dextrose 5% and bupivacaine with dextrose.
• The implicated batches were produced by Swaroop Pharmaceuticals, Otsuka Pharmaceutical India and Health Biotech, with expiries extending into 2026–2028.
• Punjab Health Systems Corporation has been tasked to form a committee, evaluate suspected adverse events, trace supply chains and submit a report, while samples go for lab testing.
• Hospitals have been told to identify and isolate the stock, officials have not disclosed case counts, and non‑compliance could draw departmental action following a recent Coldrif syrup withdrawal and earlier IV recalls.